12:00 AM
 | 
Mar 20, 2000
 |  BC Week In Review  |  Clinical News  |  Clinical Results

AngioMark: Phase II

EPIX said that preliminary data from 20 patients in its 45-patient U.S. Phase II trial showed signal enhancement and prolonged imaging time using AngioMark. Persistent contrast enhancement...

Read the full 115 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >